Business
Liquidia Announces Poster Presentation at the 2023 American Thoracic Society International Conference
MORRISVILLE, N.C., May 19, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced the Company will present
About this update from Liquidia Corporation
[{"type":"text","content":"MORRISVILLE, N.C., May 19, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced the Company will present data related to the investigational use of YUTREPIA™ (treprostinil) inhalation powder at the 2023 American Thoracic Society (ATS) International Conference, taking place May 19-24, 2023, in Washington, D.C. Thematic Poster Session: B64 - The Multiple Components of Pulmonary Rehabilitation Date and time: Monday, May 22, 2023, 11:30 a.m. – 1:15 p.m. ETLocation: Area J, Hall C (Lower Level), Walter E. Washington Convention CenterPresenting Author: Charles Burger, M.D., from the Mayo Clinic, Jacksonville, FloridaAbstract: Exploratory Efficacy Analysis of INSPIRE Open Label Extension Study with Inhaled Treprostinil (Yutrepia™) Following the presentation, the poster will be available on the Company’s website at http://liquidia.com/print-technology/publications/. About YUTREPIA™(treprostinil) inhalation powderYUTREPIA is an investigational, inhaled dry powder formulation of treprostinil delivered through a convenient, low-resistance, palm-sized device. On November 5, 2021, the FDA issued a tentative approval for YUTREPIA, which is indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability in adult patients with New York Heart Association (NYHA) Functional Class II-III symptoms. The FDA has confirmed that YUTREPIA may add the indication to treat pulmonary hypertension with interstitial lung disease (PH-ILD) without additional clinical studies. YUTREPIA was designed using Liquidia’s PRINT® technology, which enables the development of drug particles that are precise and uniform in size, shape, and composition, and that are engineered for enhanced deposition in the lung following oral inhalation. Liquidia has completed INSPIRE, or Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil, an open-label, multi-center phase 3 clinical study of YUTREPIA in patients diagnosed with PAH who are naïve to inhaled treprostinil or who are transitioning from Tyvaso® (nebulized treprostinil). YUTREPIA was previously referred to as LIQ861 in investigational studies. About Liquidia CorporationLiquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and ...